Abstract 29: Cost-effectiveness of Inpatient Case Management for Heart Failure Patients
Background: Prior studies have demonstrated that approximately 5.7 million Americans suffer from heart failure (HF). The direct costs of HF
Read moreBackground: Prior studies have demonstrated that approximately 5.7 million Americans suffer from heart failure (HF). The direct costs of HF
Read moreIntroduction: Administrative claims may be a low cost alternative to traditional clinical trial event adjudication, but whether claims data can
Read moreBackground: Heart disease occurs when there is reduced blood flow to the heart. It refers to a range of conditions
Read moreBackground: Immune checkpoint inhibitors (ICIs), including programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and cytotoxic lymphocyte antigen-4 (CTLA-4)
Read moreIntroduction: The morbidity and mortality associated with obesity (BMI >30 kg/m2) has been known to medical science for more than
Read moreBackground: Current guidelines for heart failure with reduced ejection fraction (HFrEF) recommend transition to an angiotensin receptor-neprilysin inhibitor (ARNI) from
Read moreBackground: Evidences support the stroke centers, including primary stroke center (PSC) and comprehensive stroke center (CSC) to improve stroke patient
Read moreIntroduction: Safety-net hospitals (SNH) treat a large population of un-insured and low income patients; several prior studies report worse outcome
Read moreBackground: Heart failure (HF) patients with aortic stenosis (AS) constitute a high-risk population posing diagnostic and therapeutic challenges. Few studies
Read moreBackground: Peripheral artery disease (PAD) prevalence is increasing by age in high-income countries. It is unknown whether patient characteristics, treatment
Read more